Please Wait...

sRANKL // Free Soluble Receptor Activator of Nuclear Factor Kappa B Ligand

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Formerly known as TNF-related activation-induced cytokine (TRANCE), the receptor activator of Nf-κB ligand (RANKL) was initially identified as an osteoprotegerin ligand (Lacey et al., 2012). RANKL is a member of the TNF superfamily and exists as a transmembrane protein and in a soluble form (after proteolytic cleavage or alternative mRNA splicing). There are three known spliced variants in human and the smallest of these three variants lacks the transmembrane and the intracellular domain and is directly secreted. The two other variants can be shed and released by proteases (MMP-3, MMP-7, MMP-14, ADAM10, ADAM17 and ADAM19) (Schramek et al., 2010). RANKL, RANK, and osteoprotegerin are a key molecular regulation system for bone remodeling. RANKL is an essential factor for the maturation and survival of osteoclasts. With the Wnt/β-catenin, they are the two major signaling pathway in regulation of bone mass (Boyce and Xing, 2007).

Bioclinica Lab employs two assays to measure RANKL. The assays are designed for the measurement of free RANKL (using recombinant osteoprotegerin for capture and polyclonal antibodies for detection) and total RANKL (sandwich immunoassay) in human serum.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (5 minutes ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of…
bioclinica (10 minutes ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (26 minutes ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil…
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace…
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c…
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen